Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.
GLUE has been the subject of several other research reports. JPMorgan Chase & Co. decreased their price objective on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an "overweight" rating for the company in a research note on Friday, August 7th. UBS Group assumed coverage on shares of Monte Rosa Therapeutics in a research report on Sunday, October 11th. They set a "buy" rating and a $19.00 target price on the stock. Wells Fargo & Company dropped their target price on shares of Monte Rosa Therapeutics from $27.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday. HC Wainwright started coverage on shares of Monte Rosa Therapeutics in a research report on Thursday, October 1st. They set a "buy" rating and a $25.00 price target on the stock. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price target on shares of Monte Rosa Therapeutics in a research note on Tuesday, August 25th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $26.44.
Read Our Latest Analysis on GLUE
Monte Rosa Therapeutics Stock Performance
Shares of Monte Rosa Therapeutics stock opened at $10.57 on Friday. Monte Rosa Therapeutics has a 52-week low of $9.68 and a 52-week high of $25.77. The firm has a 50-day moving average of $11.70 and a 200-day moving average of $17.09. The stock has a market cap of $901.73 million, a PE ratio of -7.55 and a beta of 1.40.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.24. The company had revenue of $54.37 million for the quarter, compared to analysts' expectations of $33.87 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. Equities research analysts predict that Monte Rosa Therapeutics will post -1.13 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in GLUE. Allworth Financial LP purchased a new position in shares of Monte Rosa Therapeutics in the 2nd quarter valued at about $30,000. China Universal Asset Management Co. Ltd. boosted its holdings in Monte Rosa Therapeutics by 14.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,166 shares of the company's stock valued at $202,000 after acquiring an additional 2,121 shares during the last quarter. Sterling Capital Management LLC raised its holdings in shares of Monte Rosa Therapeutics by 842.3% in the 3rd quarter. Sterling Capital Management LLC now owns 2,450 shares of the company's stock valued at $29,000 after acquiring an additional 2,190 shares in the last quarter. Profund Advisors LLC boosted its stake in Monte Rosa Therapeutics by 7.6% in the 3rd quarter. Profund Advisors LLC now owns 32,406 shares of the company's stock worth $387,000 after purchasing an additional 2,295 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of Monte Rosa Therapeutics during the third quarter valued at about $48,000. 79.96% of the stock is currently owned by hedge funds and other institutional investors.
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell's natural protein-degradation machinery. The company's approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.
Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.